Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Optimizing treatment for Ph+ ALL: TKIs combined with chemotherapy followed by transplantation

Josep-Maria Ribera • 4 Sep 2024
SOHO 2024
Acute Lymphoblastic Leukemia Leukemia Dasatinib Imatinib Ponatinib

Josep-Maria Ribera, MD, PhD, Institut Català d’Oncologia Badalona, Barcelona, Spain, discusses the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), highlighting the combination of tyrosine kinase inhibitors (TKIs) with chemotherapy, followed by potential consolidation with stem cell transplantation. Prof. Ribera also explores how third-generation TKis, such as ponatinib, may reduce the need for transplantation. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Josep-Maria Ribera

Exciting ALL updates from ASH 2024 5:07
Exciting ALL updates from ASH 2024
Josep-Maria Ribera • 29 Nov 2024
The prognostic impact of genetic risk at baseline is associated with MRD clearance in adult Ph- ALL 1:42
The prognostic impact of genetic risk at baseline is associated with MRD clearance in adult Ph- ALL
Josep-Maria Ribera • 29 Nov 2024
Ponatinib versus imatinib monotherapy after combination with chemotherapy in newly diagnosed Ph+ ALL 1:50
Ponatinib versus imatinib monotherapy after combination with chemotherapy in newly diagnosed Ph+ ALL
Josep-Maria Ribera • 29 Nov 2024
Comparing the outcomes of AYA and older adults with Ph- ALL in the PETHEMA LAL19 trial 1:08
Comparing the outcomes of AYA and older adults with Ph- ALL in the PETHEMA LAL19 trial
Josep-Maria Ribera • 29 Nov 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals